文献速递骨软组织肉瘤与黑色素瘤

安罗替尼治疗晚期肉瘤的疗效与安全性

[Efficacy and safety of Anlotinib in the treatment of advanced sarcoma].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2023-01-01

该研究回顾性分析45例接受安罗替尼单药治疗的晚期肉瘤患者,评估疗效与安全性并分析不良反应与疗效的关系。结果显示腺泡状软组织肉瘤与滑膜肉瘤疗效优于其他亚型,出现手足综合征者无进展生存期更长。

要点

  • 腺泡状软组织肉瘤、滑膜肉瘤的疾病控制率优于骨肉瘤(均P<0.05)。
  • 出现手足综合征者无进展生存期长于未出现者(14.10个月 vs 6.00个月,P=0.024)。
  • 常见不良反应为促甲状腺素升高(17.8%,8/45)、贫血(15.6%,7/45)、乏力(11.1%,5/45)。

核心结论

  • 安罗替尼治疗腺泡状软组织肉瘤、滑膜肉瘤的疗效优于其他亚型。
  • 治疗后出现手足综合征患者的无进展生存期明显长于未出现手足综合征的患者。

研究设计与样本

  • 回顾性分析2018年6月至2021年8月在郑州大学附属肿瘤医院接受安罗替尼治疗的45例晚期肉瘤患者的临床资料。

主要发现

  • 40例用药超过1.5个月并接受疗效评价,3个月客观缓解率为7.5%(3/40),疾病控制率为80.0%(32/40)。
  • 全组整体客观缓解率为2.5%(1/40),疾病控制率为27.5%(11/40),中位无进展生存期为6.70个月。
  • 腺泡状软组织肉瘤中位无进展生存期为10.27个月,长于其他亚型肉瘤(P=0.048)。
  • 腺泡状软组织肉瘤、滑膜肉瘤的疾病控制率分别为100.0%(5/5)和100.0%(9/9),明显优于骨肉瘤的25.0%(1/4),均P<0.05。
  • 出现手足综合征者无进展生存期为14.10个月,未出现者为6.00个月(P=0.024)。

关键数值与推荐

  • 客观缓解率与疾病控制率按实体肿瘤疗效评价标准1.1版计算。
  • 常见不良反应:促甲状腺素升高17.8%(8/45)、贫血15.6%(7/45)、乏力11.1%(5/45)。
  • 5例患者治疗后出现3级不良反应。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: Patients with advanced sarcomas have a dismal prognosis with few effective therapies. The purpose of this study was to evaluate the efficacy and safety of anlotinib in the treatment of advanced sarcoma and to explore the relationship between adverse events (AEs) and efficacy. Methods: Data from 45 advanced sarcoma patients who received anlotinib monotherapy at Affiliated Cancer Hospital of Zhengzhou University between June 2018 and August 2021 were retrospectively analyzed. According to Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1, the objective remission rate (ORR) and disease control rate (DCR) were calculated, and the progression free survival (PFS) and treatment-related AEs were recorded and analyzed. Survival analysis was conducted using the Kaplan-Meier survival rates were compared using the Log rank test. Results: Forty patients were treated for more than 1.5 months and received efficacy evaluation. The ORR and DCR after 3 months were 7.5%(3/40) and 80.0%(32/40), respectively. The overall ORR was 2.5%(1/40), the total DCR was 27.5%(11/40), and the median progression-free survival (m-PFS) was 6.70 months; The m-PFS of alveolar soft tissue sarcoma (ASPS) was 10.27 months, which was significantly longer than that of other subtypes of sarcoma (P=0.048). In addition, the DCR of ASPS and synovial sarcoma (SS) was significantly better than that of osteosarcoma (P<0.05). The most common AEs were elevated thyroid stimulating hormone (17.8%, 8/45), anemia (15.6%, 7/45), fatigue (11.1%, 5/45). Five patients developed grade 3 AEs after treatment; The PFS of patients with hand-foot syndrome after treatment was significantly longer than that of patients without hand-foot syndrome (14.10 vs 6.00, P=0.024). Conclusions: The efficacy of anlotinib in the treatment of ASPS and SS is better than that of other subtypes. The PFS in the group with hand-foot syndrome was significantly longer than that of the group without hand-foot syndrome. 目的: 探讨安罗替尼治疗晚期肉瘤的有效性和安全性,分析不良反应与疗效间的关系。 方法: 回顾性分析2018年6月至2021年8月在郑州大学附属肿瘤医院接受安罗替尼治疗的45例晚期肉瘤患者的临床资料。根据实体肿瘤疗效评价标准1.1版计算客观缓解率(ORR)和疾病控制率(DCR),分析无进展生存时间(PFS)与治疗相关不良反应间的关系,生存分析采用Kaplan-Meier法,生存率的比较采用Log rank检验。 结果: 45例患者中,40例患者用药时间超过1.5个月,3个月ORR为7.5%(3/40),DCR为80.0%(32/40)。全组患者的整体ORR为2.5%(1/40),DCR为27.5%(11/40),中位PFS为6.70个月。腺泡状软组织肉瘤患者中位PFS为10.27个月,长于其他亚型的肉瘤患者(P=0.048),腺泡状软组织肉瘤、滑膜肉瘤患者的DCR[分别为100.0%(5/5)和100.0%(9/9)]明显优于骨肉瘤患者[(25.0%(1/4),均P<0.05]。常见的不良反应有促甲状腺素升高(17.8%,8/45)、贫血(15.6%,7/45)、乏力(11.1%,5/45)等,5例患者治疗后出现了3级不良反应。治疗后出现手足综合征患者的PFS(14.10个月)长于未出现手足综合征的患者(6.00个月,P=0.024)。 结论: 安罗替尼治疗腺泡状软组织肉瘤、滑膜肉瘤的疗效优于其他亚型,治疗后出现手足综合征患者的PFS明显长于未出现手足综合征的患者。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Yan Q, Yao WT, Du XH, et al. [Efficacy and safety of Anlotinib in the treatment of advanced sarcoma]. Zhonghua Zhong Liu Za Zhi. 2023. PMID: 37875427. doi:10.3760/cma.j.cn112152-20210820-00632

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。